Clinical Trial: In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07586709) titled 'In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms' on April 20.

Brief Summary: This study aims to assess the safety profile of in vivo BCMA/GPRC5D-targeted CAR-T cell immunotherapy in patients with relapsed or refractory plasma cell neoplasms.

Study Start Date: May 09

Study Type: INTERVENTIONAL

Condition: Plasma Cell Neoplasms

Intervention: DRUG: In vivo BCMA/GPRC5D Tandem Dual CAR-T cell

Administration of in vivo BCMA/GPRC5D tandem dual CAR-T cells. Three dose levels (dose A, dose B, dose C) will be evaluated using a standard 3+3 dose-escalation design.

Recruitment Status: NOT_YET_RE...